CN113813287A - Preparation method of compound medicinal liquid for treating verruca vulgaris - Google Patents
Preparation method of compound medicinal liquid for treating verruca vulgaris Download PDFInfo
- Publication number
- CN113813287A CN113813287A CN202110992342.6A CN202110992342A CN113813287A CN 113813287 A CN113813287 A CN 113813287A CN 202110992342 A CN202110992342 A CN 202110992342A CN 113813287 A CN113813287 A CN 113813287A
- Authority
- CN
- China
- Prior art keywords
- mixture
- preparation
- verruca vulgaris
- treating
- liquid medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010153 skin papilloma Diseases 0.000 title claims abstract description 33
- 201000004196 common wart Diseases 0.000 title claims abstract description 28
- 239000007788 liquid Substances 0.000 title claims abstract description 22
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 12
- -1 nano silver ions Chemical class 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000012752 auxiliary agent Substances 0.000 claims abstract description 6
- 239000012153 distilled water Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000003961 penetration enhancing agent Substances 0.000 claims abstract description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- RZXLPPRPEOUENN-UHFFFAOYSA-N Chlorfenson Chemical compound C1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=C(Cl)C=C1 RZXLPPRPEOUENN-UHFFFAOYSA-N 0.000 claims description 3
- 241000755716 Convallaria Species 0.000 claims description 3
- 235000009046 Convallaria majalis Nutrition 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 229940069521 aloe extract Drugs 0.000 claims description 3
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 claims description 3
- OCBHHZMJRVXXQK-UHFFFAOYSA-M benzyl-dimethyl-tetradecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 OCBHHZMJRVXXQK-UHFFFAOYSA-M 0.000 claims description 3
- SXPWTBGAZSPLHA-UHFFFAOYSA-M cetalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SXPWTBGAZSPLHA-UHFFFAOYSA-M 0.000 claims description 3
- 229960000228 cetalkonium chloride Drugs 0.000 claims description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 3
- 150000002191 fatty alcohols Chemical class 0.000 claims description 3
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 3
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 229940105902 mint extract Drugs 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 8
- 208000000260 Warts Diseases 0.000 description 5
- 241000701806 Human papillomavirus Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000020737 peppermint extract Nutrition 0.000 description 1
- 201000004303 plantar wart Diseases 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a preparation method of compound medicinal liquid for treating verruca vulgaris, which comprises the steps of uniformly mixing benzalkonium chloride and nano silver ions with the concentration of 25ppm to obtain a mixture A; adding a permeation aid into the mixture A to obtain a mixture B; adding an auxiliary agent into the mixture B to obtain a mixture C; dissolving the mixture C in ethanol and distilled water to obtain a liquid medicine for treating verruca vulgaris; carrying out clinical test on the verruca vulgaris treating liquid medicine; the invention adopts benzalkonium chloride and nano silver ions to form a compound medicament, can effectively treat common wart, is easy to absorb active ingredients by matching with a penetration enhancer, and also contains an auxiliary medicament, thereby being beneficial to the recovery of affected parts, reducing the recurrence rate and meeting the clinical urgent need of the treatment of common wart.
Description
Technical Field
The invention relates to a preparation method of a compound liquid medicine for treating verruca vulgaris, belonging to the technical field of biological medicines.
Background
The common wart is an epidermal benign neoplasm caused by Human Papilloma Virus (HPV), and is clinically common in common wart, plantar wart, flat wart, condyloma acuminatum and the like; warts are treated by taking wart body destruction, local skin growth regulation and local or general immune reaction stimulation as main means, and a large number of common wart patients are clinically treated at present, but the main treatment method is refrigeration or laser, so that the wound is large, the pain is strong, and the recurrence is high; at present, quaternary ammonium salt medicaments represented by benzalkonium chloride are proved to be capable of treating wart diseases, so that the defects of the existing wart treatment can be effectively overcome by preparing benzalkonium chloride compound medicaments.
Disclosure of Invention
In view of the above technical problems, the present invention aims to: provides a preparation method of a compound liquid medicine for treating verruca vulgaris.
The technical solution of the invention is realized as follows: a preparation method of a compound liquid medicine for treating verruca vulgaris comprises the following steps:
uniformly mixing benzalkonium chloride and nano silver ions with the concentration of 25ppm to obtain a mixture A;
adding a permeation aid into the mixture A to obtain a mixture B;
thirdly, adding an auxiliary agent into the mixture B to obtain a mixture C;
dissolving the mixture C in ethanol and distilled water to obtain a verruca vulgaris treating liquid medicine, wherein the final concentration of nano silver ions is 10 ppm;
fifthly, carrying out clinical test on the verruca vulgaris treating liquid medicine.
Preferably, in the step (i), the benzalkonium chloride is a compound of dodecyl dimethyl benzyl ammonium chloride, tetradecyl dimethyl benzyl ammonium chloride and hexadecyl dimethyl benzyl ammonium chloride.
Preferably, in the step (c), the penetration enhancer is one or a combination of polyvinyl alcohol, ethoxy diglycol, fatty alcohol polyoxyethylene ether sulfonate and isopropanol.
Preferably, in the third step, the auxiliary agent is one or more of peppermint extract, lily of the valley extract, pink extract and aloe extract.
Due to the application of the technical scheme, compared with the prior art, the invention has the following advantages:
the invention provides a preparation method of a compound liquid medicine for treating verruca vulgaris, wherein benzalkonium chloride and nano silver ions are adopted to form a compound medicine, the compound medicine can be used for effectively treating the verruca vulgaris, an osmosis promoter is matched to enable active ingredients to be easily absorbed, and the medicine also contains an auxiliary medicine, so that the medicine can be beneficial to recovery of affected parts, reduce the recurrence probability and meet the clinical urgent need of verruca vulgaris treatment.
Detailed Description
The present invention will be described with reference to examples.
The preparation method of the compound liquid medicine for treating verruca vulgaris, disclosed by the invention, comprises the following steps of:
uniformly mixing benzalkonium chloride and nano silver ions with the concentration of 25ppm to obtain a mixture A; wherein the benzalkonium chloride can be a compound of dodecyl dimethyl benzyl ammonium chloride, tetradecyl dimethyl benzyl ammonium chloride and hexadecyl dimethyl benzyl ammonium chloride; the optimal combination ratio of benzalkonium chloride and nano silver ion can be obtained by orthogonal method antiviral experiment.
② adding a permeation assistant agent into the mixture A to obtain a mixture B, wherein the permeation assistant agent can be one or a combination of polyvinyl alcohol, ethoxy diglycol, fatty alcohol polyoxyethylene ether sulfonate and isopropanol.
And thirdly, adding an auxiliary agent into the mixture B to obtain a mixture C, wherein the auxiliary agent can be one or a combination of more of mint extract, lily of the valley extract, pink extract and aloe extract.
Fourthly, the mixture C is dissolved in ethanol and distilled water according to a certain proportion to obtain the liquid medicine for treating the verruca vulgaris, and the final concentration of nano silver ions is 10 ppm.
Fifthly, the liquid medicine for treating the verruca vulgaris is clinically tested, and the liquid medicine can be put into use after the drug effect is fully verified.
The above-mentioned embodiments are merely illustrative of the technical idea and features of the present invention, and the purpose thereof is to enable those skilled in the art to understand the contents of the present invention and implement the present invention, and not to limit the scope of the present invention, and all equivalent changes or modifications made according to the spirit of the present invention should be covered in the scope of the present invention.
Claims (5)
1. A preparation method of a compound liquid medicine for treating verruca vulgaris is characterized by comprising the following steps:
uniformly mixing benzalkonium chloride and nano silver ions to obtain a mixture A;
adding a permeation aid into the mixture A to obtain a mixture B;
thirdly, adding an auxiliary agent into the mixture B to obtain a mixture C;
fourthly, the mixture C is dissolved in ethanol and distilled water to obtain the liquid medicine for treating the verruca vulgaris;
fifthly, carrying out clinical test on the verruca vulgaris treating liquid medicine.
2. The preparation method of the compound liquid medicine for treating verruca vulgaris according to claim 1, wherein the preparation method comprises the following steps:
in the step I, benzalkonium chloride is a compound of dodecyl dimethyl benzyl ammonium chloride, tetradecyl dimethyl benzyl ammonium chloride and hexadecyl dimethyl benzyl ammonium chloride.
3. The preparation method of the compound liquid medicine for treating verruca vulgaris according to claim 1, wherein the preparation method comprises the following steps:
in the step I, the concentration of the nano silver ions is 25 ppm.
4. The preparation method of the compound liquid medicine for treating verruca vulgaris according to claim 1, wherein the preparation method comprises the following steps:
in the second step, the penetration enhancer is one or a combination of polyvinyl alcohol, ethoxy diglycol, fatty alcohol polyoxyethylene ether sulfonate and isopropanol.
5. The preparation method of the compound liquid medicine for treating verruca vulgaris according to claim 1, wherein the preparation method comprises the following steps:
in the step III, the auxiliary medicament is one or a combination of more of mint extract, lily of the valley extract, pink extract and aloe extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110992342.6A CN113813287A (en) | 2021-08-27 | 2021-08-27 | Preparation method of compound medicinal liquid for treating verruca vulgaris |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110992342.6A CN113813287A (en) | 2021-08-27 | 2021-08-27 | Preparation method of compound medicinal liquid for treating verruca vulgaris |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113813287A true CN113813287A (en) | 2021-12-21 |
Family
ID=78913683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110992342.6A Pending CN113813287A (en) | 2021-08-27 | 2021-08-27 | Preparation method of compound medicinal liquid for treating verruca vulgaris |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113813287A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102380059A (en) * | 2011-10-25 | 2012-03-21 | 王绪友 | Composite traditional Chinese medicine preparation for removing flat warts |
| CN104522050A (en) * | 2015-01-07 | 2015-04-22 | 安徽瀚驰生物科技有限公司 | Composite bactericide of nano-silver and polyhexamethylene guanidine and processing technology of composite bactericide |
| CN106822265A (en) * | 2017-04-01 | 2017-06-13 | 杨涵 | A kind of environment-friendly type antibiotic inactivator for treating human papilloma virus infection |
| CN111388414A (en) * | 2020-03-06 | 2020-07-10 | 深圳埃米迦医药生物科技有限公司 | Application of silver amethoxide antiviral solution in preparation of medicine for resisting HPV (human papillomavirus) |
| CN111408733A (en) * | 2020-04-24 | 2020-07-14 | 安信生物科技有限公司 | Antibacterial and antiviral nano silver colloidal solution and preparation method and application thereof |
| CN111991498A (en) * | 2020-09-04 | 2020-11-27 | 长沙重链抗体研究院 | Heavy chain antibody composite gel for treating HPV and preparation method thereof |
-
2021
- 2021-08-27 CN CN202110992342.6A patent/CN113813287A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102380059A (en) * | 2011-10-25 | 2012-03-21 | 王绪友 | Composite traditional Chinese medicine preparation for removing flat warts |
| CN104522050A (en) * | 2015-01-07 | 2015-04-22 | 安徽瀚驰生物科技有限公司 | Composite bactericide of nano-silver and polyhexamethylene guanidine and processing technology of composite bactericide |
| CN106822265A (en) * | 2017-04-01 | 2017-06-13 | 杨涵 | A kind of environment-friendly type antibiotic inactivator for treating human papilloma virus infection |
| CN111388414A (en) * | 2020-03-06 | 2020-07-10 | 深圳埃米迦医药生物科技有限公司 | Application of silver amethoxide antiviral solution in preparation of medicine for resisting HPV (human papillomavirus) |
| CN111408733A (en) * | 2020-04-24 | 2020-07-14 | 安信生物科技有限公司 | Antibacterial and antiviral nano silver colloidal solution and preparation method and application thereof |
| CN111991498A (en) * | 2020-09-04 | 2020-11-27 | 长沙重链抗体研究院 | Heavy chain antibody composite gel for treating HPV and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 姚日生: "《药用高分子材料》", 30 April 2008 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7902258B2 (en) | Methods for preventing lesions caused by viruses of the Herpesviridae or Poxviridae family | |
| WO1993000873A1 (en) | Composition and method for transdermal delivery of diclofenac | |
| CN108992451A (en) | A kind of emulsifiable paste and preparation method thereof with anti-inflammatory anti-itch antibiotic effect | |
| EP1372389B1 (en) | Virucidal compositions | |
| CN102283899B (en) | Traditional Chinese medicine external preparation and application thereof | |
| CN113813287A (en) | Preparation method of compound medicinal liquid for treating verruca vulgaris | |
| CN101756886A (en) | Imiquimod micro emulsion gels for local skin and preparation method thereof | |
| AU2002251933A1 (en) | Virucidal compositions | |
| WO2024041083A1 (en) | Antifungal solution, preparation method therefor, and use thereof | |
| CN102579483A (en) | Emulsion liniment for curing mild burn and preparation method thereof | |
| KR20130009590A (en) | Anti-wart pharmaceutical composition and method for treating wart | |
| CN116077422B (en) | Pomegranate seed oil diglyceride nanoemulsion gel | |
| CN102423293B (en) | Microemulsion gel preparation of oxiconazole nitrate | |
| CN106619518B (en) | Imperatorin flexible liposome and preparation method and application thereof | |
| CN109876007B (en) | Ozone antibacterial and disinfecting gel and preparation method thereof | |
| CN101375845B (en) | Podophyllotoxin external-use formulation prescription for treating pointed condyloma and herpes genitalis, dosage form series and preparation method | |
| CN104721234A (en) | Periplaneta Americana extract product ion-activated in-situ gel and preparation method thereof | |
| CN104274494B (en) | A kind of American cockroach external preparation and preparation method thereof | |
| CN112263544A (en) | Lidocaine hydrochloride gel and preparation method thereof | |
| CN111821363A (en) | Liquid dressing applied to superficial wound surface and peripheral skin care and application method thereof | |
| CN105434431B (en) | A kind of multi-functional externally used antimicrobial preparation and its preparation method and application | |
| CN115192518A (en) | Medicinal gel preparation for treating hydrofluoric acid-caused skin burn and preparation method thereof | |
| CN113713000B (en) | Main medicine component composition for treating sore carbuncle, burn, scald and acne, sustained and controlled release pharmaceutical preparation, and preparation method and application thereof | |
| CN102133324B (en) | Ointment for treating skin burns and scalds | |
| CN113491666A (en) | Gel containing phenol and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211221 |
|
| RJ01 | Rejection of invention patent application after publication |